2.25亿收购、5亿股票回购、CEO将离职：凯杰刚刚发布3则重磅消息

Core Insights - QIAGEN announced a cash acquisition of Pars e Biosciences for $225 million to enhance its sample preparation technology in the rapidly growing single-cell sequencing market, enabling scalable research solutions for millions to billions of cells [1][2] - The CEO of QIAGEN, Thierry Bernard, stated that the integration of Pars e will significantly strengthen their product offerings in a vital area of life sciences, facilitating the generation of large datasets necessary for predictive virtual cell models and AI-driven drug discovery [2] - QIAGEN also revealed a $500 million stock buyback plan, which, combined with direct capital repayment and reverse stock split, is expected to be completed by January 7, 2026, delivering approximately $1.15 billion to shareholders ahead of the $1 billion target set for 2028 [3][4] Financial Performance - For Q3 2025, QIAGEN reported net sales of $533 million, a 6% year-over-year increase, with core business sales also growing by 6% at constant exchange rates. Adjusted diluted earnings per share were $0.61, exceeding analyst expectations of $0.59 [2][3] Leadership Changes - Concurrently with the announcements, it was disclosed that CEO Thierry Bernard will resign after a successor is appointed. Bernard has been with QIAGEN since 2015 and has served as CEO since 2019 [5]